CD274 and neoplasm: Tumour cells also express PD-L1, but notably, PD-L1 expression by TAMs specifically correlates with efficacy of immune checkpoint blockade (ICB) therapies (13–15) and is required for responses to anti-PD-L1 in murine cancer models (16).